Antigenics Inc., of New York, appointed Brian Corvese to its board.

ARCA Discovery Inc., of Denver, added J. William Freytag to its board.

Astion Pharma A/S, of Copenhagen, Denmark, appointed Lars Smedegaard Andersen president and CEO. He was executive vice president, commercial affairs.

Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., appointed Keith Katkin president and CEO, and elected him to the board.

Bioheart Inc., of Sunrise, Fla., appointed William Pinon president and CEO.

Conformia, of Sunnyvale, Calif., appointed Vineet Gulati managing director, FDA-Conformia CRADA research study.

Cytochroma Inc., of Markham, Ontario, appointed co-founder P. Martin Petkovich full-time chief scientific officer.

Discovery Laboratories Inc., of Doylestown, Pa., appointed W. Thomas Amick chairman. Herbert McDade Jr. will remain as a director.

Gilead Sciences Inc., of Foster City, Calif., appointed Norbert Bischofberger executive vice president, research and development and chief scientific officer. It also appointed John Milligan chief operating officer.

ITI Life Sciences, of Dundee, Scotland, appointed Jim Greaves director of marketing and communications.

NeoStem Inc., of New York, hired Arlene Graime as director, government affairs and special projects.

Northwest Biotherapeutics Inc., of Bothell, Wash., appointed Jim Johnston chief financial officer.

Novavax Inc., of Rockville, Md., elected John Lambert executive chairman. He replaced Gary Evans, who assumed the position of lead director. It also appointed James Robinson vice president of technical and quality operations.

Pacgen Biopharmaceuticals Corp., of Vancouver, British Columbia, appointed Robert DuFresne president and CEO. Former CEO and co-founder David Cheng remained as director and chief scientific officer.

Pharmasset Inc., of Princeton, N.J., appointed Fredric Price to its board and audit committee.

Sepragen Corp., of Hayward, Calif., added George Martinez to its board.

The New York Biotechnology Association, of New York, named Nathan Tinker executive director.

Vasogen Inc., of Mississauga, Ontario, said Chairman Terrance Gregg succeeded David Elsley as president and CEO. Elsley, who founded Vasogen, remained a director.

No Comments